资源描述：
《伊马替尼耐药的慢性粒细胞白血病患者bcr—abl基因atp结合位点点突变的检测》由会员上传分享，免费在线阅读，更多相关内容在教育资源-天天文库。
1、伊马替尼耐药的慢性粒细胞白血病患者bcr—abl基因ATP结合位点点突变的检测?566?参考文献2007年8月第28卷第8期ChinJHematol,August2007,Vol28,No..81StorbR.DeegHj,Whiteheadj,eta1.Methotrexateandcyclosporinecomparedwithcyclosporinealoneforprophylaxisofacutegraftversushostdiseaseaftermarrowtransplantationforleukemi
2、a.NEnglJMed,1986,314:729-735.2MohtyM,Lava:ladeHD,FaucherC,eta1.Mycophenolatemofetilandcyclosporineforgraft-versus—hostdiseaseprophylaxisfollowingre.ducedintensityconditioningallogeneicstemcelltransplantation.BoneMarrowTransplant,2004,34:527-530.3王健民,宋献民,章卫平,等.霉酚酸
3、酯联合环孢素和甲氨蝶呤预防外周血干细胞移植后急性移植物抗宿主病.中华医学杂志,2002,82:507-510.4BolwellB,SobecksR,PohlmanB,eta1.Aprospectiverandomizedtrialcomparingcyclosporineandshortcoursemethotrexatewithcyclos.porineandmycophenolatemofetilforGVHDprophylaxisinmyeloabla-tireallogeneicbonenlaiTowtransp
4、lantation.BoneMarrowTransplant,2004,34:621-625.5NeumannF,GraefT,TapprichC,eta1.CyclosporineAandmyco-phenolatemofetilVScyclosporineAandmethotrexateforgraft.versus.hostdiseaseprophylaxisafterstemcelltransplantationfromHLA—iden'ticalsiblings.BoneMarrowTransplant,200
5、5,35:1089-1093.6PrzepiorkaD,WeisdorfD,MartinP,eta1.1994consensusconferenceonacuteGVHDgrading.BoneMarrowTransplant,1995,15:825-828.7SchulmanHM.SullivanKM,WeidenPL,eta1.Chronicgraft-versus—hostsyndromeinman.AlongtermclinicopathologicstudyofSeatlepatients.AmJMed,198
6、0,69:204-217.8BornhauserM,SchulerU,PorksenG,eta1.Mycophenolatemofetilandcyclosporineasgraft-versus-hostdiseaseprophylaxisafteralloge—neicbloodstemcelltransplantation.Transplantation,1999,67:499-5o4.9PohlreichD,VitekA,MaaloufJ,eta1.Decreasedriskofacutegastro—intes
7、tinaltoxicitywhensubstitutingmethotrexatewithmycophenolatemofetilinthepreventionofgraft-versus-hostdiseaseinstemcelltrans-plantationfollowingmyeloablativeconditioningregimens.BoneMar'rowTransplant,2006,37:235237.(收稿日期:2006-09-05)伊马替尼耐药的慢性粒细胞白血病患者bcr—abl基因ATP结合位点点
8、突变的检测杨东光张日岑建农朱子玲慢性粒细胞白血病(CML)为一种起源于骨髓内异常多能干细胞的骨髓增殖性疾病,以持续表达bcr—abl融合基因为特征,这段融合基因的翻译产物bcr—abl蛋白具有较高的蛋白酪氨酸激酶活性,可激活一系列下游信号传导通路而导致CML的发生,因而成为CML治疗的明确靶向.伊马替尼(IM)可竞争
